Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBig Technologies Regulatory News (BIG)

Share Price Information for Big Technologies (BIG)

Share Price is delayed by 15 minutes
Get Live Data
104.50    0.00 (0.00%)
Bid:
104.50
Ask:
106.00
Spread: 1.50 (1.435%)
Market Cap: £305.38m
BIG Live PriceLast checked at - London Stock Exchange

Intraday Big Technologies Share Chart

Trading Statement

19 Jan 2024 07:04

RNS Number : 2821A
Big Technologies PLC
19 January 2024

19 January 2024

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Big Technologies plc

("Big Technologies" or the "Company" and the "Group")

Trading Update

Big Technologies plc, the UK-based remote people monitoring technology company, issues the following trading update ahead of the announcement scheduled for 26 March 2024 of its full year results for the year ended 31 December 2023.

The Group has continued to perform in line with the board's expectations with revenue for the year ended 31 December 2023 expected to be approximately Β£55 million (2022: Β£50.2 million) and adjusted EBITDA to be approximately Β£33 million (2022: Β£30.5 million). These results are in line with current market expectations1.

Outlook for 2024

Revenue from our contract to provide electronic monitoring services to one of our larger customers, based in Colombia, is expected to end during the first half of 2024. This contract has been subject to short term renewals since September 2021. A number of recent new contract wins are expected to partially offset the potential revenue loss from Colombia.

During the second half of 2023, we have significantly expanded our business development efforts in the US market, the largest market in the world for electronic monitoring and substance detection. We expect this investment to accelerate sales growth in the medium term, but the additional costs are expected to reduce operating profit margins in the US in 2024 until new sales are realised.

As a result of these developments, we expect Group sales for 2024 to be at least at the level achieved in 2022. More detailed guidance for 2024 will be given at the time of our results in March when the outcome in Colombia is known with greater certainty.

The Group continues to see opportunities to expand market share and scale-up the business and is in the process of releasing its first innovative substance detection technology to priority customers. We have enjoyed contract renewals across the business and won a number of new customers in recent months which will start to contribute revenues during 2024 and 2025. A return to growth is expected for 2025 and beyond.

1: The Company has compiled forecasts from four analysts with current market forecasts for 2023 revenue to be in the range of Β£54.0 to Β£54.5m, with a consensus of Β£54.3m, and for adjusted EBITDA to be in the range of Β£32.7m to Β£32.8m, with a consensus of Β£32.7m.

Sara Murray OBE, Chief Executive Officer, commented:

"In difficult market conditions, 2023 has seen the Group deliver a strong performance with continued growth in sales, profits and our cash reserves. We continue to invest in the business and in our market-leading suite of monitoring products and expect to see growth in the coming years. We are obviously disappointed with the outcome in Colombia, with a customer that we have served well for a number of years. We see a pipeline of attractive business opportunities around the globe and will continue to work diligently to replace this revenue stream."

For further information please contact:

Big Technologies

+44 (0) 19 2360 1910

Sara Murray (Chief Executive Officer)

Daren Morris (Chief Financial Officer)

Zeus (Nominated Adviser and Sole Broker)

+44 (0) 20 3829 5000

Jamie Peel / Dan Bate / Kieran Russell (Investment Banking)

Benjamin Robertson (Equity Capital Markets)

About Big Technologies

Big Technologies is the parent company of Buddi, which was founded in 2005 by its current CEO, Sara Murray, following an initial idea to create a GPS device small enough for a child to carry. Today, Big Technologies is a proven supplier of innovative and high-quality products and services to the remote personal monitoring industry. Big Technologies provides products and services under a number of brand and trading names, with 'Buddi' being the most well-known and being used in respect of activities within the core criminal justice market. Big Technologies (under the buddi brand) has created a leading, integrated technology platform (including both hardware and software solutions) for remote monitoring of individuals, providing state-of-the-art Electronic Monitoring (EM) solutions on a SaaS-like, subscription basis.

Electronic Monitoring in the criminal justice sector involves utilising location technologies to remotely monitor and manage people at all stages of the criminal justice system. The Company's focus on the Criminal Justice market in the immediate term has been demand-driven, with significant opportunities created by a combination of favourable market tailwinds as electronic location devices are increasingly recognised as alternatives to imprisonment, and superior technological capability enabling the Company to meet this demand effectively.

Big Technologies' criminal justice solution has been iteratively developed over a 10-year period, utilising the knowledge of an experienced management team listening to customers. The solution consists of a proprietary software platform with modular monitoring hardware, capable of being adapted to multiple applications. The Company's criminal justice solution is principally focussed around the "Buddi Smart Tag", an electronic monitoring hardware device, and "Buddi Eagle", the in-house developed, cloud-based monitoring software. Collectively, the hardware and the intelligent tools integrated into Big Technologies' software enable real-time tracking of monitored individuals with high levels of accuracy and reliability. Buddi evidences a substantial reduction in false alerts when compared to competitor systems which, combined with the reduction in subsequent investigations, can result in substantial cost savings for customers.

In addition to the high levels of accuracy, the Buddi Smart Tag has several key advantages over its competitors' devices. The tag is lighter, smaller, has longer battery life and offers a simple, contact free and shorter installation process, providing substantial staff cost savings for customers. This superior product design, coupled with the intelligent monitoring software, typically comes at a small price premium to competitor devices. However, the overall effectiveness and reliability of the solution, combined with the substantial cost savings delivered as a result of reduced monitoring costs, have helped Big Technologies deliver strong revenue growth from both existing and new customers. The Company leases its devices and software solutions to customers typically based on daily or monthly rates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
TSTGZGMMNLMGDZG
Date   Source Headline
27th May 20267:00 amRNSNotice of AGM
30th Mar 20267:00 amRNSAudited Results for the year to 31 December 2025
26th Feb 20267:00 amRNSHolding(s) in Company
3rd Feb 20267:00 amRNSBoard Changes
2nd Feb 20267:00 amRNSHolding(s) in Company
27th Jan 20267:00 amRNSFull Year Trading Update
19th Jan 20267:00 amRNSFurther Litigation Update
10th Dec 20259:41 amRNSHolding(s) in Company
9th Dec 20259:42 amRNSHolding(s) in Company
8th Dec 20257:00 amRNSTrading Update
3rd Nov 20252:54 pmRNSDirector and PDMR Dealings
16th Oct 20257:01 amRNSWithdrawal of General Meeting Requisition Notice
16th Oct 20257:00 amRNSBoard Changes
3rd Oct 20257:00 amRNSBoard Changes
30th Sep 20257:00 amRNSInterim Results for the 6 months to 30 June 2025
26th Sep 20257:00 amRNSNotice of Requisition of a General Meeting
12th Sep 20257:00 amRNSLitigation Update
20th Aug 20257:00 amRNSChange of Website Address
6th Aug 20257:00 amRNSBoard Change and Issue of Shares
1st Aug 20257:00 amRNSIssue of Shares
28th Jul 20257:00 amRNSBoard Changes
22nd Jul 20257:00 amRNSTrading Update
18th Jun 20252:53 pmRNSResult of AGM and Litigation Update
13th Jun 20258:12 amRNSPublication of Letter to Shareholders
10th Jun 20251:27 pmRNSSuspension of Voting Rights and Letter Response
5th Jun 20257:00 amRNSLitigation Update
22nd May 20259:45 amRNSDirector Dealings
22nd May 20257:00 amRNS2024 Audited Results and Notice of AGM
16th May 20257:00 amRNSAppointment of Joint Corporate Broker
8th May 20257:00 amRNSBoard and Management Changes and Trading Update
7th Apr 20257:00 amRNSAppointment of Non Executive Director
3rd Apr 20257:00 amRNSUpdate re: CEO Dismissal
1st Apr 20257:00 amRNS-RContract Award
1st Apr 20257:00 amRNSDirectorate Change
1st Apr 20257:00 amRNSTransaction in Own Shares
31st Mar 20255:20 pmRNSCEO Dismissal and Commencement of Litigation
27th Mar 20257:00 amRNSTransaction in Own Shares
26th Mar 20257:00 amRNSTransaction in Own Shares
25th Mar 20257:00 amRNSTransaction in Own Shares
24th Mar 20257:00 amRNSHolding(s) in Company
24th Mar 20257:00 amRNSTransaction in Own Shares
21st Mar 202511:13 amRNSLitigation Update
21st Mar 20257:00 amRNSTransaction in Own Shares
20th Mar 20257:00 amRNSTransaction in Own Shares
19th Mar 20257:00 amRNSTransaction in Own Shares
18th Mar 202512:51 pmRNSCEO Suspension
18th Mar 20257:00 amRNSTransaction in Own Shares
14th Mar 20257:00 amRNSTransaction in Own Shares
13th Mar 20257:00 amRNSTransaction in Own Shares
12th Mar 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.